

Product datasheet for SR301506

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Factor XII (F12) Human siRNA Oligo Duplex (Locus ID 2161)

Product data:

Product Type: siRNA Oligo Duplexes

Purity: HPLC purified

Quality Control: Tested by ESI-MS

Sequences: Available with shipment

Stability: One year from date of shipment when stored at -20°C.

of transfections: Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final

conc. 10 nM).

Note: Single siRNA duplex (10nmol) can be ordered.

RefSeq: <u>NM 000505</u>

UniProt ID: P00748

Synonyms: HAE3; HAEX; HAF

Components: F12 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 2161)

Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol


Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml

Summary: This gene encodes coagulation factor XII which circulates in blood as a zymogen. This single

chain zymogen is converted to a two-chain serine protease with an heavy chain (alpha-factor XIIa) and a light chain. The heavy chain contains two fibronectin-type domains, two epidermal growth factor (EGF)-like domains, a kringle domain and a proline-rich domain, whereas the light chain contains only a catalytic domain. On activation, further cleavages takes place in the heavy chain, resulting in the production of beta-factor XIIa light chain and the alpha-factor XIIa light chain becomes beta-factor XIIa heavy chain. Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then to beta-factor XIIa. The active factor XIIa participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. It activates coagulation factors VII and XI. Defects in this gene do not cause any clinical symptoms and the sole effect is that whole-

blood clotting time is prolonged. [provided by RefSeq, Jul 2008]







Performance Guaranteed:

OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).